Market research
VTFN.F Vitrolife AB (publ)
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.67
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- SE0011205202
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.67
About
About Vitrolife AB (publ)
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.
Research context
Vitrolife AB (publ) appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the VTFN.F discussion.
5 years, 6 months ago
Vitrolife AB (publ) is currently in a long term uptrend where the price is trading 52.6% above its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 22.8.
Vitrolife AB (publ)'s total revenue sank by 6.6% to $382M since the same quarter in the previous year.
Its net income has increased by 11.5% to $107M since the same quarter in the previous year.
Finally, its free cash flow grew by 27.9% to $164M since the same quarter in the previous year.
Based on the above factors, Vitrolife AB (publ) gets an overall score of 4/5.